# Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis

> **NCT00505089** · PHASE1,PHASE2 · TERMINATED · sponsor: **Novartis** · enrollment: 11 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** ACZ885
- **DRUG:** ACZ885
- **DRUG:** ACZ885
- **DRUG:** ACZ885

## Key facts

- **NCT ID:** NCT00505089
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2009-05
- **Final completion:** —
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2009-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00505089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00505089, "Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00505089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*